Kojin Therapeutics is #Hiring. We are looking for a team member with deep knowledge of state-of-the-art computational chemistry techniques, deployed to accelerate small-molecule drug discovery. Learn more about this position here: https://bit.ly/3QKoSfx #Chemists #Biotech
Kojin Therapeutics
Biotechnology Research
Boston, Massachusetts 4,772 followers
Developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology
About us
Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and cardiovascular, immunologic, and degenerative diseases. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis. The Kojin founding team brings together leadership in chemical biology, genetics, immunology, cancer therapeutics, and drug discovery and development, and includes: Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan.
- Website
-
https://www.kojintx.com
External link for Kojin Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
451 D St
Suite 502
Boston, Massachusetts 02210, US
Employees at Kojin Therapeutics
-
Hongjie Hu
-
Tarangini (Gini) Deshpande
-
Sally Kokernak Millwood
Senior Administrative and Operations Manager at Kojin Therapeutics
-
Luba Greenwood, J.D.
Chief Executive Officer I Managing Partner at Dana-Farber Cancer Institute Venture Fund I Healthcare I Life Sciences I Tech Investor & Executive I…
Updates
-
We are looking for talented #Pharmacologists to work in our #collaborative environment advancing novel small-molecule therapeutics that modulate ferroptosis. View our open roles for Preclinical In Vivo and Molecular Pharmacologists: https://bit.ly/4aL0eDv #Hiring #biotech
-
-
Kojin Therapeutics is hiring Medicinal/Organic Chemists. Learn more about the positions and our team harnessing groundbreaking discoveries in cell-state and ferroptosis biology: https://bit.ly/3JZFWKL #hiring #Biotech #Chemists
-
-
Become a ferroptosis pioneer at Kojin Therapeutics. Join our growing scientific team and help lead the way in developing new #cancer medicines that induce #ferroptosis. #biotech #drugdiscovery
We are hiring Molecular Cell Biologists and Chemical Biologists. Join the innovative Kojin Therapeutics #drugdiscovery team developing first-in-class medicines for patients with #cancer and other difficult-to-treat diseases. Apply now: https://bit.ly/4aobQv3 #hiring #biotech #biologists
-
-
We are hiring Molecular Cell Biologists and Chemical Biologists. Join the innovative Kojin Therapeutics #drugdiscovery team developing first-in-class medicines for patients with #cancer and other difficult-to-treat diseases. Apply now: https://bit.ly/4aobQv3 #hiring #biotech #biologists
-
-
At Kojin Therapeutics, we are dedicated to building a #collaborative team and allowing them to flourish in an energetic environment. We know that groundbreaking science takes cohesive teamwork. Come join us. https://lnkd.in/eek3qHmU #Hiring #drugdiscovery #biotechnology
-
-
Kojin therapeutics is harnessing groundbreaking discoveries in cell-state and #ferroptosis #biology and cutting-edge #drugdiscovery to develop first-in-class treatments for use in patients with #cancer and other diseases – and we are #hiring. #biotechnology https://bit.ly/4aL0eDv
-
-
Yesterday at JPM Healthcare Week our new CEO Harvey Berger spoke with BiotechTV founder Brad Loncar. Listen to their conversation, here:
𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Biotech veteran Harvey Berger is back at the helm of a biotech company. He tells us why he joined Kojin Therapeutics. He describes the science of ferroptosis and his experience working with Kojin's scientific founder Stuart Schreiber. He also shares a few memories of the beginnings of the biotech sector. Full video: https://lnkd.in/g-GNk5QP BiotechTV's coverage of SF Healthcare Week is brought to you by: HSBC Innovation Banking.
-
Describing Alexandria as a “one-of-kind, once-in-a-generation” company hardly does it justice. It is so much more. Alexandria has been the lifeblood of our industry — willing to join with entrepreneurs and life-science tenants in taking risks and creating new eco-systems. ARE’s founder, Joel Marcus brought together unexpected insights into real estate & venture capital along with industry-specific legal acumen to found, build, and lead a powerhouse in our industry.
Today, Alexandria celebrates the 30th anniversary of our one-of-a-kind, once-in-a-generation company — a truly special milestone in our history. Since 1994, we have been relentless in our drive to catalyze life-changing innovation to benefit human health. As we reflect on 30 remarkable years and look ahead, we thank our tenants for putting their trust in us and for their continued efforts to advance groundbreaking medical innovations to improve and save lives. We also thank our investors for their confidence in our company and our incredible team for their operational excellence and dedication to our mission-driven business each and every day. Read more: https://lnkd.in/gjzNeuvn
-
-
Incredible start to the newest chapter in my biotech life. Kojin scientists and collaborators are an amazing group, and I am proud to be part of the team. I anticipate great things from my new colleagues. Tame the fire for the good of humanity (the meaning of Kojin).
We are thrilled to announce the appointment of Dr. Harvey Berger, a physician-scientist and biotech-industry veteran with over 35 years of experience, as our new chairman, president, and chief executive officer. Welcome to Kojin, Harvey! For full details and to learn more about Dr. Berger, read today’s press release on our website: https://kojintx.com/ Dr. Berger founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global-oncology company. In this and other leadership roles, he spearheaded the development and approval of six innovative, breakthrough medicines for patients with cancer, cardiovascular disease, and autoimmune disease, as well as a cancer-diagnostic blood test.
-